

# IMPACT FUNDING

**Ludwig Cancer Research** is an international community of distinguished scientists dedicated to preventing and controlling cancer.

American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts enabled by his resources have grown to encompass the Ludwig Institute and the Ludwig Centers at six U.S. institutions, all pursuing breakthroughs to alter the course of cancer. Ludwig Cancer Research has committed \$2.5 billion to cancer research, with \$900 million in dedicated funding to the institutions that house the Ludwig Centers. Impact funding provides scientists sustainable support, giving them the freedom to pursue discoveries that lead to new treatments. This innovative funding approach is designed to maximize capital and encourage high-risk, high-reward cancer research.

## Our Centers

Established in 2006, the Ludwig Centers are dedicated cancer research laboratories at six leading U.S. institutions. Although the Centers operate independently of the Institute, their directors and scientists work collaboratively with each other and with the Institute, engaging in life-changing science to reduce the burden of cancer.

[www.ludwigcancerresearch.org](http://www.ludwigcancerresearch.org)



**Joan Brugge**  
Harvard

“Ludwig support provides resources that will empower us to forge highly collaborative teams of cancer experts to develop innovative ideas that will lead to novel treatment strategies to combat cancer.”



**George D. Demetri**  
Harvard

“We want to make cancer therapies more predictive, reliable and effective. That’s the transformational power of this Ludwig investment in research. Increasing the investment allows us to do it faster and better.”



**Geoffrey L. Greene**  
University of Chicago

“Ludwig funding has allowed us to carry out true bench to bedside research, in particular to develop novel nuclear receptor targeted therapies that have application in advanced breast, prostate and ovarian cancers.”



**Kenneth W. Kinzler**  
Johns Hopkins

“Ludwig’s unique support allowed us to be the first group to sequence cancer at a genome-wide scale, and thereby determine the basic features of cancer genome landscapes.”



**Alexander Y. Rudensky**  
Memorial Sloan-Kettering

“Impact funding allows us to pursue high-risk research from preclinical to early stage clinical trials, spearheading the development of novel immunological therapeutic approaches for cancer treatment.”



**Bert Vogelstein**  
Johns Hopkins

“By virtue of the flexible funding from Ludwig, we can kickstart new projects, hire the best young scientists and initiate collaborations in a way that is impossible through conventional means of support.”



**Ralph R. Weichselbaum**  
University of Chicago

“Ludwig funding allows us to explore new areas of molecular diagnosis and therapeutics for patients with metastasis, attracting the brightest and best minds to our Center.”



**Robert A. Weinberg**  
MIT

“With this increased support, our six research groups at MIT can continue to be powerhouses of metastasis research.”



**Irving Weissman**  
Stanford

“Thanks in large part to the Ludwig funding, we have been able to quickly translate a fundamental discovery about how cancer evades detection by the immune system into clinical testing for a broad array of cancers.”